Question:

Are there any new pass-through drugs for the upcoming quarter?

Answer:

The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:

C9030 Injection, copanlisib, 1 mg
C9031 Lutetium Lu 177, dotatate, therapeutic, 1 mCi
C9032 Injection, voretigene neparvovec-rzyl, 1 billion vector genome
Q9991 Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg
Q9992 Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg
Q9995 Injection, emicizumab-kxwh, 0.5 mg

 

Facebook
Twitter
LinkedIn

CPT® copyright 2024 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

Unlock 50% off all 2024 edition books when you order by July 5! Use the coupon code CO5024 at checkout to claim this offer!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24